Helix BioPharma’s product development initiatives include its novel L-DOS47 new ADC candidate for the treatment of several different cancers with overexpression of CEACAM6. For more information contact Investor Relation or Shareholder Services.

Helix BioPharma and its Board of Directors believe that transparent and sound corporate governance practices are critical to the Company’s long-term success. The Corporation believes that its corporate governance practices are well suited to its size and stage of development, after taking into account the guidelines published by the Canadian securities regulatory authorities, and promote the effective functioning of the Board and its Committees.

Latest News